Business Context and Reporting Period
This Form 8-K was filed by pSivida Corp. (not Eyepoint, Inc.) on September 11, 2014, reporting events occurring on September 8, 2014. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer appointments and does not contain financial statements.
Material Changes
- Board Election: The Board of Directors elected James Barry as a Director.
- Executive Background: Dr. Barry currently serves as Executive Vice President and Chief Operating Officer of InspireMD.
- Compensatory Arrangement: Dr. Barry received an initial grant of an option to purchase 40,000 shares of pSivida Corp. common stock.
- Option Terms: The exercise price is $4.77 per share. The options vest in three equal portions on the first, second, and third anniversaries of the grant date and remain exercisable until the tenth anniversary.
- Condition: The grant is subject to shareholder approval.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. The document is strictly a notification of a director appointment and associated equity compensation.
Investor Verification Checklist
- Verify the shareholder approval status of the 40,000 share option grant to James Barry.
- Confirm the exact vesting schedule dates based on the September 8, 2014 grant date.
- Review the total outstanding option pool to assess the dilution impact of this new grant.
- Check for any subsequent filings regarding Dr. Barry's tenure or changes to the Board composition.